Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, founded in 2015. The company focuses on developing innovative cancer immunotherapies, targeting well-understood biological pathways to enhance safety and efficacy for patients. Their approach emphasizes combination therapies that leverage the synergistic potential of small molecules and antibodies. Arcus has a robust pipeline of investigational drugs aimed at various cancers, including Casdatifan for kidney cancer, Domvanalimab for gastrointestinal and lung cancers, and Quemliclustat for pancreatic and lung cancers, among others. The company is known for its rapid progression of drug candidates, advancing them from early discovery to clinical development in as little as 18 months. With a dedicated team of over 600 employees, Arcus fosters a collaborative culture focused on scientific innovation and a patient-centered mission.